3 High Beta ETFs To Consider As Wall Street Welcomes Court Ruling On Tariffs, Tech Rebound
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 29 2025
0mins
Source: Benzinga
Market Reaction to Court Decision: A U.S. court ruling has halted President Trump's ability to impose broad tariffs, leading to a positive market response, especially with strong earnings from NVIDIA and a temporary pause in U.S.-EU trade tensions.
High-Beta ETFs for Investors: With the market's bullish sentiment, three high-beta ETFs—Invesco S&P 500 High Beta ETF, ProShares Ultra S&P 500, and Fidelity Blue Chip Growth ETF—are highlighted as potential investment opportunities for traders looking to capitalize on short-term momentum.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVDA
Wall Street analysts forecast NVDA stock price to rise
41 Analyst Rating
39 Buy
1 Hold
1 Sell
Strong Buy
Current: 219.510
Low
200.00
Averages
264.97
High
352.00
Current: 219.510
Low
200.00
Averages
264.97
High
352.00
About NVDA
NVIDIA Corporation is an artificial intelligence (AI) infrastructure company. The Company is engaged in accelerated computing to help solve the challenging computational problems. Its segments include Compute & Networking and Graphics. The Compute & Networking segment includes its Data Center accelerated computing and networking platforms and AI solutions and software, and automotive platforms and autonomous and electric vehicle solutions, including software. The Graphics segment includes GeForce GPUs for gaming and personal computers (PCs), and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics. Its technology stack includes the foundational NVIDIA CUDA development platform that runs on all NVIDIA GPUs, as well as hundreds of domain-specific software libraries, frameworks, algorithms, software development kits (SDKs), and application programming interfaces (APIs). Its platforms address four markets, which include Data Center, Gaming, Professional Visualization, and Automotive.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nvidia Announces $80 Billion Stock Buyback Amid AI Growth
- Earnings Beat: Nvidia's first-quarter results exceeded Wall Street expectations, showcasing robust growth in its data center business amid accelerating AI infrastructure investments, which reflects management's confidence in future revenue and profit expansion.
- Massive Buyback Authorization: The board approved an additional $80 billion stock repurchase program, indicating management's belief that the current stock price is undervalued and aiming to enhance shareholder confidence through capital return.
- Historical Buyback Trends: Over the past year, Nvidia has authorized more than $25 billion in stock buybacks, demonstrating a consistent capital return strategy, particularly returning over $41.1 billion to shareholders through buybacks and dividends in fiscal 2026.
- Attractive Market Valuation: With a current P/E ratio of 25 times expected earnings, Nvidia appears relatively undervalued compared to historical premiums during AI expansion phases, making the buyback decision not just a capital return but a strong signal of future growth potential.
See More
SpaceX IPO Expected to Be Largest in History
- Massive Capital Raise: SpaceX aims to raise approximately $75 billion through its IPO, with a valuation between $1.75 trillion and $2 trillion, positioning it as potentially the largest IPO in history and attracting significant investor interest.
- Infrastructure Supplier Dependence: While SpaceX's IPO garners attention, history indicates that infrastructure suppliers like Nvidia often achieve higher long-term returns, highlighting the market's ongoing demand for essential technology support.
- Clear Funding Utilization: The IPO proceeds will be directed towards expanding the Starlink network, enhancing Starship reusability, and designing data centers that could be deployed in orbit, all of which require substantial GPU support, thereby reinforcing the partnership with Nvidia.
- Expected Market Volatility: SpaceX stock is anticipated to experience typical post-IPO volatility, particularly after lock-up periods expire when insiders may begin to take profits, while Nvidia could benefit from the influx of capital due to its dominant position in AI infrastructure.
See More
Nvidia Continues to Exceed Expectations with Record Growth
- Record Revenue: Nvidia reported a record revenue of $81.6 billion for fiscal Q1 2027, representing an 85% year-over-year increase and marking 14 consecutive quarters of revenue growth, highlighting its robust performance and sustained demand in the AI sector.
- Surge in Data Center Revenue: Data center revenue, which now constitutes the bulk of Nvidia's earnings, rose 92% year-over-year to $75.2 billion, indicating the company's leadership in cloud computing and AI infrastructure, further solidifying its market share.
- High Profit Margins Maintained: Nvidia's recent gross margin of 74.9% demonstrates its ability to maintain efficient cost control and profitability while experiencing rapid growth, enhancing investor confidence in its future prospects.
- Analysts Remain Bullish: Despite market skepticism regarding Nvidia's market cap, 52 out of 54 analysts rate the stock as a buy, with an average price target of $299, indicating a potential 35% upside from current levels and reflecting optimism about its future performance.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Nvidia's Strong Growth Persists Amid Overvaluation Claims
- Significant Revenue Growth: Nvidia's latest earnings report reveals a record revenue of $81.6 billion for Q1 2027, marking an 85% year-over-year increase and achieving 14 consecutive quarters of revenue growth, showcasing its robust performance in the AI sector.
- Surge in Data Center Revenue: Data center revenue, which constitutes the bulk of Nvidia's earnings, soared by 92% year-over-year to $75.2 billion, further solidifying its leadership position in the high-margin market.
- Relatively Reasonable Valuation: Despite Nvidia's market cap exceeding $5 trillion, its forward P/E ratio stands at 25 times, significantly lower than AMD's 61 times and Broadcom's 37 times, indicating investment attractiveness amid strong profitability.
- Analysts Remain Bullish: Among the 54 analysts covering Nvidia, 52 have rated it a buy, with an average price target of $299, suggesting a 35% upside from the current stock price, reflecting market confidence in its future growth.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
Nvidia Announces $80 Billion Stock Buyback Amid AI Growth
- Earnings Beat: Nvidia's first-quarter results exceeded Wall Street expectations, showcasing robust growth in its data center business amid accelerating AI infrastructure investments, which reflects management's confidence in future revenue and profit expansion.
- Massive Buyback Authorization: The board approved an additional $80 billion stock repurchase program, indicating management's belief that the current stock price is undervalued and aiming to enhance shareholder confidence through capital return.
- Historical Buyback Trends: Over the past year, Nvidia has authorized more than $25 billion in stock buybacks, demonstrating a consistent capital return strategy, particularly returning over $41.1 billion to shareholders through buybacks and dividends in fiscal 2026.
- Attractive Market Valuation: With a current P/E ratio of 25 times expected earnings, Nvidia appears relatively undervalued compared to historical premiums during AI expansion phases, making the buyback decision not just a capital return but a strong signal of future growth potential.
See More
SpaceX IPO Expected to Be Largest in History
- Massive Capital Raise: SpaceX aims to raise approximately $75 billion through its IPO, with a valuation between $1.75 trillion and $2 trillion, positioning it as potentially the largest IPO in history and attracting significant investor interest.
- Infrastructure Supplier Dependence: While SpaceX's IPO garners attention, history indicates that infrastructure suppliers like Nvidia often achieve higher long-term returns, highlighting the market's ongoing demand for essential technology support.
- Clear Funding Utilization: The IPO proceeds will be directed towards expanding the Starlink network, enhancing Starship reusability, and designing data centers that could be deployed in orbit, all of which require substantial GPU support, thereby reinforcing the partnership with Nvidia.
- Expected Market Volatility: SpaceX stock is anticipated to experience typical post-IPO volatility, particularly after lock-up periods expire when insiders may begin to take profits, while Nvidia could benefit from the influx of capital due to its dominant position in AI infrastructure.
See More
Nvidia Continues to Exceed Expectations with Record Growth
- Record Revenue: Nvidia reported a record revenue of $81.6 billion for fiscal Q1 2027, representing an 85% year-over-year increase and marking 14 consecutive quarters of revenue growth, highlighting its robust performance and sustained demand in the AI sector.
- Surge in Data Center Revenue: Data center revenue, which now constitutes the bulk of Nvidia's earnings, rose 92% year-over-year to $75.2 billion, indicating the company's leadership in cloud computing and AI infrastructure, further solidifying its market share.
- High Profit Margins Maintained: Nvidia's recent gross margin of 74.9% demonstrates its ability to maintain efficient cost control and profitability while experiencing rapid growth, enhancing investor confidence in its future prospects.
- Analysts Remain Bullish: Despite market skepticism regarding Nvidia's market cap, 52 out of 54 analysts rate the stock as a buy, with an average price target of $299, indicating a potential 35% upside from current levels and reflecting optimism about its future performance.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Nvidia's Strong Growth Persists Amid Overvaluation Claims
- Significant Revenue Growth: Nvidia's latest earnings report reveals a record revenue of $81.6 billion for Q1 2027, marking an 85% year-over-year increase and achieving 14 consecutive quarters of revenue growth, showcasing its robust performance in the AI sector.
- Surge in Data Center Revenue: Data center revenue, which constitutes the bulk of Nvidia's earnings, soared by 92% year-over-year to $75.2 billion, further solidifying its leadership position in the high-margin market.
- Relatively Reasonable Valuation: Despite Nvidia's market cap exceeding $5 trillion, its forward P/E ratio stands at 25 times, significantly lower than AMD's 61 times and Broadcom's 37 times, indicating investment attractiveness amid strong profitability.
- Analysts Remain Bullish: Among the 54 analysts covering Nvidia, 52 have rated it a buy, with an average price target of $299, suggesting a 35% upside from the current stock price, reflecting market confidence in its future growth.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
